Related Experiment Video
Updated: May 11, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation--focus on the elderly
Gregory Y H Lip1, Deirdre A Lane
1University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, B18 7QH, UK. g.y.h.lip@bham.ac.uk
Insights
Elderly patients with atrial fibrillation (AF) benefit from oral anticoagulants (OACs) for stroke prevention, showing a positive benefit-risk balance despite increased bleeding risks. Treatment decisions should consider individual patient factors.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Atrial fibrillation (AF) significantly increases stroke risk, particularly in aging populations.
- Oral anticoagulants (OACs) are effective stroke preventatives but are underutilized in elderly patients due to bleeding concerns.
Purpose of the Study:
- To evaluate the efficacy and safety of OACs in elderly patients with AF.
- To compare treatment effects in elderly versus younger patients.
- To determine the net clinical benefit of OACs for elderly individuals.
Main Methods:
- Systematic review and evaluation of clinical study data.
- Analysis of efficacy (stroke/systemic embolism) and safety (bleeding events) of OACs.
- Comparison of vitamin K antagonists and newer OACs in different age groups.
Main Results:
- Elderly patients face higher risks for both thromboembolic and bleeding events.
- OACs demonstrated significant efficacy in stroke prevention, with comparable bleeding risks to controls in most studies.
- Newer OACs (apixaban, rivaroxaban) showed no age-related interaction in treatment effects versus warfarin; dabigatran showed increased extracranial bleeding in older patients.
Conclusions:
- Oral anticoagulant therapy offers a favorable benefit-risk profile for elderly patients with atrial fibrillation.
- OACs are effective in reducing stroke risk in the elderly.
- Individualized treatment decisions for stroke prevention in AF should balance potential benefits, risks, and patient preferences.
Abstract:
Atrial fibrillation (AF) is a major risk factor for stroke and the prevalence increases with age. Oral anticoagulants (OACs) are effective, but underused in elderly patients, primarily because of concerns about bleeding. Clinical study data on the efficacy (stroke/systemic embolism) and safety (bleeding events) of OACs in elderly patients with AF, including studies of vitamin K antagonists and newer OACs, were evaluated to determine whether treatment effects vary in elderly vs. younger patients, and whether OACs provide a net clinical benefit for elderly patients. In general, elderly patients had greater risk of both thromboembolic and bleeding events compared with younger patients. Nevertheless, OACs were associated with significant efficacy, with most studies reporting no difference in the risk of bleeding relative to control treatments. In trials of the newer OACs, no interaction was seen between age and relative treatment effects for apixaban or rivaroxaban compared with warfarin, although the rates of extracranial bleeding events increased in older patients treated with dabigatran. In conclusion, OAC therapy is associated with a positive benefit-risk balance in elderly patients. Irrespective of age, treatment decisions regarding stroke thromboprophylaxis in all patients with AF should be based on consideration of individual potential benefits and risks of treatment and patient preferences.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pharmacodynamics in Geriatric Patients: Effects of Age
Atherosclerosis IV: Nursing Management
